Wanda French-Brown Article Examines ITC Options for Hatch-Waxman Litigation

Articles / May 3, 2017

Counsel Wanda French-Brown authored an article published April 19, 2017, by Law360. The article, “The ITC’s Potential Role in Hatch-Waxman Litigation,” examines whether a branded pharmaceutical company can (or should) use the U.S. International Trade Commission (ITC) as a forum to block the importation of active pharmaceutical ingredients (API), any intermediates of the API, or finished generic drug products in the context of Hatch-Waxman litigation.

Read the article.